(Q37387951)

20 August 2017

1 reference

title

Multiple sclerosis beyond EDSS: depression and fatigue (English)

1 reference

20 August 2017

0 references

Tjalf Ziemssen

1 reference

20 August 2017

language of work or name

1 reference

1 February 2009

1 reference

Journal of the Neurological Sciences

20 August 2017

published in

1 reference

20 August 2017

volume

277 Suppl 1

1 reference

20 August 2017

page(s)

S37-41

1 reference

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Depression and quality of life in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Brain-immune communication psychoneuroimmunology of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Major depression in multiple sclerosis: a population-based perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Depression and multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

An examination of suicidal intent in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Psychoneuroimmunology--cross-talk between the immune and nervous systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Structural brain abnormalities in multiple sclerosis patients with major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Treatment of depression for patients with multiple sclerosis in neurology clinics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Glatiramer acetate: mechanisms of action in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Psychiatric side effects of interferon-beta in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

The Goldman Consensus statement on depression in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Physiopathology and treatment of fatigue in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Fatigue in multiple sclerosis: definition, pathophysiology and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

The effect of immunomodulatory treatment on multiple sclerosis fatigue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970011-5

10.1016/S0022-510X(09)70011-5

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference